contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


cyxone-welcomes-a-renewed-engagement-by-professor-rikard-holmdahl-as-scientific-advisor

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö. 

Cyxone

Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company's projects in autoimmune diseases.Rikard Holmdahl has long...

<div class="abstract">Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company's projects in autoimmune diseases.</div>Rikard Holmdahl has long established experience and expert knowledge in immunology and autoimmune diseases. Professor Holmdahl is one of Sweden's leading scientists in immunology who has contributed to very valuable insights into the mechanisms causing chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. He has during his career been acknowledged with several prestigious scientific prizes for his pioneering research.Professor Holmdahl is a member of the Royal Swedish Academy of Sciences and has also been part of the Nobel Assembly between 2014 and 2021. Since 2008, Holmdahl has led a world-leading team of scientists in inflammatory diseases at Karolinska Institute (KI) and has been one of the leading scientists behind the discovery of Cyxone's drug candidate rabeximod.Professor Rikard Holmdahl comments: "I am looking forward to continuing following the exciting development of rabeximod and in the best possible way supporting Cyxone's team in their efforts to bring this interesting drug candidate to the market. Rabeximod is a unique molecule developed by Swedish scientists based on the assumption it could block inflammation. Using preclinical models, we later understood that it was efficient for treatment of arthritis, and we also got some useful ideas of its function. On that basis a clinical trial was conducted which demonstrated a relevant therapeutic effect, but we also thought it could be further improved by changing the treatment protocol, which Cyxone now is exploring in a very interesting way.""It is an honor that Professor Holmdahl now re-engages in Cyxone's Scientific Advisory Board and actively demonstrates his great interest to continue to support rabeximod in the development of a treatment which has the potential to fulfill unmet medical needs for patients with rheumatoid arthritis. Rikard Holmdahl has been a valuable part in establishing the rabeximod project from the start. He is very knowledgeable in the processes causing the diseases where we see opportunities to use rabeximod, and he also has a large established network in the scientific community which is extremely valuable to a company like Cyxone", says Carl-Magnus Högerkorp, CEO of Cyxone.ContactCarl-Magnus Högerkorp, CEO Tel: +46 (0)70 781 88 12 Email: carl.hogerkorp@cyxone.comAbout CyxoneCyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

Stay up to date with our newsletter